Risk-guided strategy to prevent cytomegalovirus associated complications after liver transplantation. (July 2018)

• Record Type: Journal Article
• Authors: Weiler, Nina; Trötschler, Sven; Vermehren, Johannes; Schnitzbauer, Andreas A; Bechstein, Wolf O; Herrmann, Eva; Zeuzem, Stefan; Welker, Martin-Walter
• Is Part Of: Future virology. Volume 13:Number 7(2018)
• Page Start: 483
• Page End: 491
• Publication Date: 2018-07
• Subjects: CMV -- liver transplantation -- pre-emptive therapy -- prophylaxis -- valganciclovir; Virology -- Periodicals; Virus diseases -- Treatment -- Periodicals; 616.9101
• DOI: 10.2217/fvl-2018-0045
• Languages: English
• ISSNs: 1746-0794

Abstract

Aim: We evaluated a risk-guided strategy to prevent cytomegalovirus-associated complications (CMV-ac) after liver transplantation (LT).Patients & methods: Forty liver graft recipients were stratified according to their CMV risk status to prophylactic (high risk, HR and group) or pre-emptive antiviral treatment (intermediate, IR, and low risk, LR and group). A detailed analysis of clinical and virological data was performed.Results: 8/40 patients were classified within the HR, 28/40 within the IR and 4/40 within the LR group. Incidence of CMV viremia was 3/8 (38%) in the HR, 9/28 (32%) in the IR and 0/5 in the LR group. Mortality rate of CMV-ac was 0%.Conclusion: A risk-guided antiviral strategy is effective to prevent severe CMV-ac up to 1 year after LT.